Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOSNASDAQ:ACHLNASDAQ:ALLRNASDAQ:PYRGF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$1.02-2.9%$1.04$0.86▼$3.60$63.60M0.09292,950 shs135,912 shsACHLAchilles Therapeutics$1.48$1.48$0.63▼$1.51$60.83M1.25618,654 shsN/AALLRAllarity Therapeutics$0.85-5.1%$0.96$0.61▼$20.44$13.07M-0.141.11 million shs616,266 shsPYRGFPyroGenesis Canada$0.39+1.1%$0.33$0.30▼$0.80$73.57M0.7911,023 shs29,870 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals-2.86%0.00%-9.73%-20.31%-66.56%ACHLAchilles Therapeutics0.00%0.00%0.00%+7.25%+64.43%ALLRAllarity Therapeutics-5.23%-17.96%-29.58%+5.80%-95.23%PYRGFPyroGenesis Canada+1.05%+20.59%+22.16%-6.17%-8.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABOSAcumen Pharmaceuticals2.6437 of 5 stars3.72.00.00.03.31.70.6ACHLAchilles TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AALLRAllarity Therapeutics0.5493 of 5 stars0.04.00.00.01.60.00.6PYRGFPyroGenesis CanadaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 3.33Buy$7.33618.95% UpsideACHLAchilles Therapeutics 0.00N/AN/AN/AALLRAllarity Therapeutics 0.00N/AN/AN/APYRGFPyroGenesis Canada 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ALLR, ABOS, PYRGF, and ACHL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025ABOSAcumen PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.003/28/2025ABOSAcumen PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $11.00(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$4.61 per shareN/AACHLAchilles TherapeuticsN/AN/AN/AN/A$3.49 per shareN/AALLRAllarity TherapeuticsN/AN/AN/AN/A($559.39) per shareN/APYRGFPyroGenesis Canada$9.14M8.05N/AN/A($0.01) per share-39.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$52.37M-$1.94N/AN/AN/AN/A-32.99%-27.99%8/12/2025 (Estimated)ACHLAchilles Therapeutics-$69.67M-$1.65N/AN/AN/AN/A-54.45%-47.68%8/12/2025 (Estimated)ALLRAllarity Therapeutics-$11.90MN/A0.00N/AN/AN/A-369.67%-100.06%8/4/2025 (Estimated)PYRGFPyroGenesis Canada-$21.12M-$0.02N/A∞N/A-115.14%N/A-60.81%N/ALatest ALLR, ABOS, PYRGF, and ACHL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ABOSAcumen Pharmaceuticals-$0.56-$0.48+$0.08-$0.48N/AN/A5/13/2025Q1 2025ALLRAllarity Therapeutics-$8.10-$0.25+$7.85-$0.25N/AN/A3/27/2025Q4 2024ABOSAcumen Pharmaceuticals-$0.47-$0.62-$0.15-$0.62N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/AACHLAchilles TherapeuticsN/AN/AN/AN/AN/AALLRAllarity TherapeuticsN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.1410.4310.43ACHLAchilles TherapeuticsN/A6.046.04ALLRAllarity TherapeuticsN/A2.752.75PYRGFPyroGenesis CanadaN/A0.600.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%ACHLAchilles Therapeutics56.38%ALLRAllarity Therapeutics11.53%PYRGFPyroGenesis Canada0.03%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals9.30%ACHLAchilles Therapeutics5.38%ALLRAllarity Therapeutics0.08%PYRGFPyroGenesis Canada47.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2060.57 million55.81 millionOptionableACHLAchilles Therapeutics25041.10 million38.89 millionNot OptionableALLRAllarity Therapeutics1015.08 million4.43 millionNot OptionablePYRGFPyroGenesis Canada90186.69 million96.34 millionNo DataALLR, ABOS, PYRGF, and ACHL HeadlinesRecent News About These CompaniesHigh-Tech Micro Cap Rallies After Securing Boeing Supplier StatusMay 29 at 6:57 PM | msn.comPyroGenesis Confirms Receiving Accelerated Customer Request for Fumed Silica SamplesMay 28 at 7:30 AM | globenewswire.comPyroGenesis Confirms Production of Fumed Silica at Pilot Scale Following Independent AnalysisMay 21, 2025 | globenewswire.comPyroGenesis Confirms Successful Collection of Material from Fumed Silica Pilot Plant BaghouseMay 15, 2025 | globenewswire.comPyroGenesis, Inc. (PYRGF) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comPyroGenesis Announces First Quarter 2025 ResultsMay 13, 2025 | globenewswire.comPyroGenesis Provides Update on Fumed Silica ProjectMay 13, 2025 | globenewswire.comPyroGenesis Closes $2,385,000 First Tranche in Previously Announced LoanMay 12, 2025 | globenewswire.comPyroGenesis Canada (NASDAQ:PYRGF) Trading Down 0.2% - Should You Sell?May 11, 2025 | marketbeat.comPyroGenesis Schedules First Quarter 2025 Financial Results and Business Update Conference CallMay 9, 2025 | globenewswire.comPyroGenesis Announces Closing of Non-Brokered Private Placement of up to $5,750,000May 5, 2025 | globenewswire.comP. Peter Pascali Updates Early Warning ReportApril 10, 2025 | globenewswire.comPyroGenesis Inc. (PYRGF) Q4 2024 Earnings Call TranscriptApril 1, 2025 | seekingalpha.comPyroGenesis Announces Fourth Quarter and Full Year 2024 ResultsMarch 31, 2025 | globenewswire.comPyroGenesis Schedules 2024 Fiscal Year Financial Results and Business Update Conference CallMarch 26, 2025 | globenewswire.comPyroGenesis Inc.: PyroGenesis Provides Update on Varennes Carbon Recycling ProjectMarch 21, 2025 | finanznachrichten.dePyroGenesis Provides Update on Varennes Carbon Recycling ProjectMarch 21, 2025 | globenewswire.comHPQ’s Statement on U.S. - Canada Tariff Situation, Reinforces Case for Domestic Fumed Silica ProductionMarch 12, 2025 | markets.businessinsider.comPyroGenesis and GE Vernova Sign Memorandum of Understanding (MOU)March 11, 2025 | globenewswire.comPyroGenesis Provides Response to Impact of U.S. TariffsMarch 4, 2025 | globenewswire.comPyroGenesis in final stages of Boeing supplier qualification for course titanium powderMarch 4, 2025 | pm-review.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALLR, ABOS, PYRGF, and ACHL Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$1.02 -0.03 (-2.86%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.02 0.00 (0.00%) As of 05/30/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Achilles Therapeutics NASDAQ:ACHL$1.48 0.00 (0.00%) As of 03/26/2025Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.Allarity Therapeutics NASDAQ:ALLR$0.84 -0.05 (-5.06%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$0.87 +0.03 (+3.43%) As of 05/30/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.PyroGenesis Canada NASDAQ:PYRGF$0.39 +0.00 (+1.05%) As of 05/30/2025 03:40 PM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
